Fig 3.

Association between week-1 metabolic response by [¹⁸F]fluorodeoxyglucose positron emission tomography (PET) /computed tomography and progression-free survival (PFS). Patients were grouped according to those with a partial metabolic response (PMR) by European Organisation for Research and Treatment of Cancer criteria, defined as > 25% decrease in maximum standardized uptake value relative to baseline v those with either stable metabolic disease (SMD) or progressive metabolic disease (PMD). PFS was calculated from the date of the landmark (week 1). (A) Cohort 1 patients with a week-1 PMR had a median PFS of 8.8 months (95% CI, 5.3 to 29.1 months) and those without a week-1 PMR had a median PFS of 1.6 months (95% lower CI, 1.4 months). (B) Cohort 2 patients with a week-1 PMR had a median PFS of 5.3 months (95% CI, 5.1 to 7.9 months) and those without a week-1 PMR had a median PFS of 3.2 months (95% CI, 1.6 to 5.3 months).